Market Flash: iSHARES MSCI Indonesia Investable Market Index Fund (EIDO:US) PRICE: 28.530 USD Down -0.360 (-1.246%) >>> BI: Rupiah Melemah Akibat Kondisi Eropa >>> Pertemuan FED pertimbangkan langkah baru dorong ekonomi >>> KIJA akan Terbitkan MEN Valas USD150 Juta >>> PT Indika Energy Perusahaan Teladan Dunia 2011 >>> Govt Promises Revision of Cost Recovery Regulation >>> BPMigas Demands PGN to Pay US$6 per MMBTU >>> Jababeka to Raise US$150 Million from Debt Markets >>> SCG Chemicals buys Chandra Asri >>> Solusi Tunas eyes Rp380 bio IPO >>> SMR Utama scouts Rp300 bio IPO >>> Alam Sutera picks two bond arrangers >>> ASII Tetap Rajai Penjualan Mobil Agustus 2011 >>> Perusahaan Thailand kuasai Saham TPIA senilai Rp 3,76 Triliun >>> Agis Main ke Tambang, Sahamnya Masuk Dalam Pengawasan >>> ACES Mendekati The Northern Agar Mau Kurangi Kepemilikan >>> IHSG masih harus berjuang terus bertahan diatas MA200 >>> Melirik Peluang Akumulasi di Saham Perbankan >>> Analisa Saham BUMI: Kuat Bertahan & Berpeluang Kembali Uptrend >>> Analisa Saham JSMR: Bertahan Di Support, What Next? >>> INDF Tertahan Di Area Support Kuat, Berpeluang Rebound >>> ASII Break Minor Support, Sell on Strength >>> ADRO Membentuk Descending Wedges, Berpeluang Rebound Terbatas >>> Wall Street ends flat as early gains evaporate >>> Fed begins policy meeting, tiptoes toward easing >>> Fed meeting to help decide on long-term Treasuries >>> Greece Makes 'Good Progress' in Reform Talks: EC >>> China worried Europe debt crisis will hit trade >>> China could roll out 4.65tr yuan stimulus package >>> IMF sees Mideast stagnation >>> NYMEX-Crude ends higher at Oct contract expiry >>> Asian Crude Palm Oil Up On Technical Buying, Soyoil >>> Foreign net Sell - 61.785.746

Rabu, 27 April 2011

Kalbe Farma posts 23.3% growth in profit - Insider Stories

Indonesia's largest pharmaceutical company PT Kalbe Farma Tbk (KLBF) announced a 23.3% increase in net profit in the first quarter of 2011 because of increase in income before tax and lowered tax expense.

The company posted Rp316 billion net profit in 1Q 2011 from Rp256 billion in 1Q 2010. Earning per share rose 23.2% to Rp34 from Rp27.
"Kalbe has been consisten in implementing its strategies to improve production cost productivity and marketing expense effectiveness," said Kalbe Finance Director Vidjongtius said in a press statement obtained by Insider Stories today. Operating profit increased 7.9% to Rp417 billion from Rp387 billion, sending Kalbe's operating margin stayed at a stable level of 17.7%. Net profit also grew 7.5% to Rp2.35 trillion from Rp2.19 trillion.

Prescription division posted Rp605 billion in sales, contributing a 28.5% to Kalbe's consolidated net sales. Consumer health division booked Rp428 billion in sales, contributed 18.2% to the company's consolidated net sales.
Nutritionals division posted Rp449 billion in sales, counted 22.9% of Kalbe's net sales. Logistic and distribution contributed 30.4% of the company's net sales.

Tidak ada komentar:

Posting Komentar